Pharma was again the top performer, with output soaring 124.3 per cent. Read more at straitstimes.com. Read more at straitstimes.com.
The York-based Aptamer Group says it ends 2025 with strong momentum as global pharma partnerships drive confidence for 2026.
59mon MSN
York biotech firm ends 2025 on high
The York-based Aptamer Group says it ends 2025 with strong momentum as global pharma partnerships drive confidence for 2026.
Capital Market on MSN
Strides Pharma slides as US arm receives 4 USFDA observations for New York facility
In an exchange filing, the company said the current Good Manufacturing Practices (cGMP) inspection was conducted by the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback